Obese Patients With Untreated Dyslipidemias

A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group, Fixed-Dose, Multi-Center Study of Weight-Reducing Effect and Safety in Obese Patients With Untreated Dyslipidemias

Status

Completed

Phases

Phase 3

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00029835

Acronym

RIO-Lipids

Enrollment

1033

Registered

2002-01-24

Start date

2001-09-30

Completion date

2003-11-30

Last updated

2009-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Dyslipidemia, Obesity

Keywords

Obesity

Brief summary

To assess the effect on weight loss and weight maintenance over a period of one year when prescribed with a hypocaloric diet in obese patients with untreated dyslipidemia

Interventions

DRUGRimonabant (SR141716)

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

18 Years to 70 Years

Healthy volunteers

Inclusion criteria

* BMI must be greater than 27 and less than 40 * Patients with untreated dyslipidemia * Stable weight (variation of less than 5 kg within 3 months prior to screening visit)

Design outcomes

Primary

Measure	Time frame
Change from baseline in body weight at 1 year.	—

Secondary

Measure	Time frame
Metabolic parameters	—

Countries

Australia, Canada, Finland, Italy, Spain, Sweden, Switzerland, United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026